NK cell expression of natural cytotoxicity receptors may determine relapse risk in older AML patients undergoing immunotherapy for remission maintenance

In a phase IV trial, eighty-four patients (age 18–79) with acute myeloid leukemia (AML) in first complete remission (CR) received cycles of immunotherapy with histamine dihydrochloride (HDC) and low-dose human recombinant interleukin-2 (IL-2) to prevent relapse in the post-consolidation phase. Aspec...

Descripción completa

Detalles Bibliográficos
Autores principales: Martner, Anna, Rydström, Anna, Riise, Rebecca E., Aurelius, Johan, Brune, Mats, Foà, Robin, Hellstrand, Kristoffer, Thorén, Fredrik B.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2015
Materias:
Research Paper: Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4767453/
https://www.ncbi.nlm.nih.gov/pubmed/26544512

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4767453/
https://www.ncbi.nlm.nih.gov/pubmed/26544512

Ejemplares similares